In the pharma industry, one of the main applications of smart robots is robotic surgical systems. This involves the design, construction, operation and application of robots in pharma research, development, and production.   

Going forward, robots can be incorporated into the healthcare system to deal with the challenges of increasing expenses, regulatory pressure, changing care and business models, and demand patterns due to ageing populations.   

Discover the leading robotics companies in the pharmaceutical industry 

Using its experience in the sector, Pharmaceutical Technology has listed some of the leading companies providing products and services related to robotics. 

The information provided in the download document is drafted for pharmaceutical executives and technology leaders involved in pharmaceutical robotics solutions. 

The download contains detailed information on suppliers and their product offerings, alongside contact details to aid purchase or hiring decisions.  

Amongst the leading suppliers of robotics in the pharmaceutical industry are Kiro Grifols, Strateos, Thermo Fisher Scientific, Zipline International, Getinge, ABB, Charles River Laboratories, Danaher (Cytiva), Multiply Labs, and Insilico Medicine. 

Robotics and smart pharma  

The Covid-19 pandemic has given businesses an unprecedented opportunity to accelerate and implement technology-fuelled changes to the way they operate, even if those changes had already begun to be implemented prior to the pandemic.   

For pharmaceutical companies, the pandemic forced many to rethink and readjust their drug development process, manufacturing, supply chains, marketing strategies, and end-customer reach.   

Trends in robotics use in pharma  

While pharmaceutical companies mainly relied on technologies before the pandemic to enhance internal processes, now digital technologies are becoming necessary to ensure business continuity and gain a competitive edge.  

The market for growth in pharmaceutical industry robotics companies is estimated to grow to $269.4m by 2028. This is partly due to the growth of robotics in the pharmaceutical industry for manufacturing, as well as the cost savings it delivers.   

Of particular significance is the use of robotics in clinical trials, along with drug discovery and development. 

Benefits of pharmaceutical industry robotics include a reduction in production downtime, reduced labour force change, improved health and safety, enhanced waste management, optimised space utilisation, and augmented production flexibility. 

Market forecasts for the pharmaceutical robotic industry 

According to GlobalData forecasts, by 2030, the robotics sector will have grown at a CAGR of 29% to $568bn. Annual growth rates will peak at 37% in 2024.  

Sales of industrial robots hit $14.6bn in 2020, equivalent to 32% of the total robotics market. By 2030, this segment will be worth $352bn, having grown at a CAGR of 38% between 2020 and 2030.  

At $30.7bn in 2020, the service robot market was larger than the industrial robots sector. However, the industrial robotics market will grow faster over the next decade.